6 terminated, 5 completed, 1 recruiting, 1 unknown. 13 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Terminated 6, Completed 5, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow fosaprepitant: new trials by email Literature Review of fosaprepitant trials Research Report on fosaprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients Fosaprepitant,ondansetron, dexamethasone, placebo ondansetron with dexamethasone - Pediatric Cancer | Phase 2 | Completed | Sun Yat-sen University | 108 | 2022-08-01 | 2024-01-09 |
| Low Dose Aprepitant for Patients Receiving Carboplatin Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Terminated | Albert Einstein College of Medicine | 15 | 2018-10-30 | 2023-11-13 |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Selinexor, Melphalan, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2017-07-20 | 2022-11-04 |
| Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy Dexamethasone, Doxorubicin, Fosaprepitant Dimeglumine - Locally Advanced Sarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2016-10-12 | 2021-08-09 |
| Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy FOSAPREPITANT (Emend), Placebo - Non-small Cell Lung Cancer, Vomiting | Phase 2 | Unknown | Ajeet Gajra | 150 | 2015-04-01 | 2015-04-03 |
| Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy Ondansetron, Placebo, Dexamethasone - CINV | Phase 2 | Completed | Acacia Pharma Ltd | 342 | 2013-10-01 | 2020-11-25 |
| Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma Fosaprepitant - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Terminated | St. Louis University | 13 | 2013-09-01 | 2018-06-07 |
| Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors Fosaprepitant, Dexamethasone, 5HT3 - Chemotherapy-Induced Nausea and Vomiting | Phase 2 | Completed | Lawrence Einhorn | 65 | 2013-01-01 | 2016-05-25 |
| Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) Fosaprepitant, Fosaprepitant Placebo, Ondansetron - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Completed | Merck Sharp & Dohme LLC | 240 | 2012-12-13 | 2019-06-25 |
| Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) Fosaprepitant dimeglumine, 5-HT3 RA, Dexamethasone - Nausea, Vomiting | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 111 | 2011-10-25 | 2018-08-27 |
| Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride - Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Terminated | University of Washington | 6 | 2009-02-01 | 2017-05-18 |
| Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy fosaprepitant dimeglumine, systemic chemotherapy, survey administration - Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Terminated | OHSU Knight Cancer Institute | 34 | 2008-08-01 | 2017-05-09 |
Vomiting (9) · Nausea (5) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Multiple Myeloma (1) · Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1) · Squamous Cell Carcinoma of Head and Neck (1) · Testicular Neoplasms (1)
Merck Sharp & Dohme LLC (2) · Acacia Pharma Ltd (1) · Ajeet Gajra (1) · Albert Einstein College of Medicine (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Lawrence Einhorn (1) · M.D. Anderson Cancer Center (1) · Montefiore Medical Center (1) · OHSU Knight Cancer Institute (1) · St. Louis University (1) · Sun Yat-sen University (1) · University of Washington (1)
United States (9) · China (1) · Denmark (1)
Ajeet Gajra, MD FACP (1) · Benjamin W Friedman, MD MS (1) · John M Richart, M.D. (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Keith Eaton (1) · Lawrence Einhorn, M.D. (1) · Richard Gralla, MD (1) · Saroj Vadhan (1) · Taiga Nishihori, M.D. (1) · Yizhuo Zhang (1)
PMID 26838019, PMID 30488222, PMID 30900392, PMID 33023948
P30CA069533 (1)